Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $20.00.

Several brokerages recently issued reports on ALT. UBS Group assumed coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley reiterated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th.

Institutional Trading of Altimmune

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its holdings in Altimmune by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock worth $156,000 after buying an additional 1,821 shares during the period. Creative Planning lifted its stake in shares of Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after acquiring an additional 3,132 shares during the period. CANADA LIFE ASSURANCE Co acquired a new position in shares of Altimmune in the first quarter worth approximately $44,000. Charles Schwab Investment Management Inc. boosted its holdings in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new stake in Altimmune during the 3rd quarter valued at approximately $31,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Stock Performance

Shares of ALT stock opened at $8.68 on Monday. Altimmune has a fifty-two week low of $2.50 and a fifty-two week high of $14.84. The company has a market cap of $617.32 million, a PE ratio of -5.60 and a beta of 0.09. The stock’s fifty day moving average price is $7.11 and its two-hundred day moving average price is $6.93.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period last year, the business earned ($0.39) earnings per share. On average, equities analysts predict that Altimmune will post -1.36 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.